Currently, most drugs used in clinical practice for renal disease, such as antioxidants, glucocorticoids, angiotensin converting enzyme (ACE) inhibitors and statins, both directly or indirectly inhibit NF-κB activation10. The gene discussed is ACE; the disease is kidney disorder.